<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0021">
 <label>21</label>
 <element-citation publication-type="journal" id="sbref02017">
  <person-group person-group-type="author">
   <name>
    <surname>Le</surname>
    <given-names>R.Q.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Yuan</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Shord</surname>
    <given-names>S.S.</given-names>
   </name>
   <name>
    <surname>Nie</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Habtemariam</surname>
    <given-names>B.A..</given-names>
   </name>
  </person-group>
  <article-title>FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome</article-title>
  <source>The Oncologist</source>
  <volume>23</volume>
  <year>2018</year>
  <fpage>943</fpage>
  <lpage>947</lpage>
  <pub-id pub-id-type="pmid">29622697</pub-id>
 </element-citation>
</ref>
